Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2022
Association between US drug price and measures of efficacy for oncology drugs approved by the US FDA from 2015 to 2020
31 October 2022 - The past five years have seen a marked increase in the number of cancer therapies on the ...
Posted by Michael Wonder on 20 Oct 2022
Drugs should be priced based on one factor – value
20 October 2022 - For a number of years, the price of drugs has drawn extraordinary attention. ...
Posted by Michael Wonder on 26 May 2022
From scientific discovery to covered treatments: understanding the payer perspective as a keystone to achieving high value care
26 May 2022 - The mission of the National Institutes of Health is to translate scientific discovery into health by designing ...
Posted by Michael Wonder on 09 May 2022
The Center for Medicare and Medicaid Innovation - toward value based care
9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...
Posted by Michael Wonder on 09 Dec 2021
Consensus lacking on ‘value’ for new anti-cancer drugs
8 December 2021 - The high price tag of new anticancer drugs has fuelled debate about the value of these treatments, ...
Posted by Michael Wonder on 14 Nov 2021
Drug pricing debate redux — should cost effectiveness analysis be used now to price pharmaceuticals?
13 November 2021 - The idea of permitting the government to negotiate pharmaceutical prices raises a question about the basis for ...
Posted by Michael Wonder on 11 Oct 2021
Paying for cancer drugs that prove their benefit
11 October 2021 - The United States pays prices for brand name drugs that are estimated to be 256% higher than ...
Posted by Michael Wonder on 09 Sep 2021
Controversy over using quality adjusted life years in cost effectiveness analyses: a systematic literature review
8 September 2021 - Researchers and policy makers in the US are exploring the implementation of health technology assessment and value ...
Posted by Michael Wonder on 22 Aug 2021
Accelerated approval - an unexpected pathway to value-based pricing?
18 August 2021 - Accelerated approval is an important regulatory pathway that provides early access to treatments for patients with serious ...
Posted by Michael Wonder on 17 Jul 2021
Aduhelm pros and cons debated at ICER meeting
16 July 2021 - Biogen officials defended the company's Alzheimer's drug and criticised ICER's cost effectiveness report today at a meeting ...
Posted by Michael Wonder on 21 Jun 2021
Are drugs priced in accordance with value? A comparison of value based and net prices using Institute for Clinical and Economic Review reports
19 June 2021 - The Institute for Clinical and Economic Review is an independent organisation that reviews drugs and devices with ...
Posted by Michael Wonder on 07 May 2021
Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it
7 May 2021 - A key element in the long-simmering debate on reining in drug prices in the United States ...
Posted by Michael Wonder on 22 Apr 2021
The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and health care systems and commercial investors
20 April 2021 - We agree that there is always likely to be some tension between commercial interests and maximising societal ...
Posted by Michael Wonder on 27 Jan 2021
On the role of cost effectiveness thresholds in health care priority setting
25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...
Posted by Michael Wonder on 04 Dec 2020
ICER opens nominations for new members of its voting panels
2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...